Science for Life Laboratory, Division of Nanobiotechnology, Department of Protein Science., Royal Institute of Technology (KTH), 171 65, Solna, Sweden.
AIMES - Center for the Advancement of Integrated Medical and Engineering Sciences (AIMES), Karolinska Institutet and KTH Royal Institute of Technology, Stockholm, Sweden.
Stem Cell Rev Rep. 2022 Oct;18(7):2494-2512. doi: 10.1007/s12015-022-10376-2. Epub 2022 Apr 30.
The generation of astrocytes from human induced pluripotent stem cells has been hampered by either prolonged differentiation-spanning over two months-or by shorter protocols that generate immature astrocytes, devoid of salient mature astrocytic traits pivotal for central nervous system (CNS) modeling. We directed stable hiPSC-derived neuroepithelial stem cells to human iPSC-derived Astrocytes (hiAstrocytes) with a high percentage of star-shaped cells by orchestrating an astrocytic-tuned culturing environment in 28 days. We employed RT-qPCR and ICC to validate the astrocytic commitment of the neuroepithelial stem cells. To evaluate the inflammatory phenotype, we challenged the hiAstrocytes with the pro-inflammatory cytokine IL-1β (interleukin 1 beta) and quantitatively assessed the secretion profile of astrocyte-associated cytokines and the expression of intercellular adhesion molecule 1 (ICAM-1). Finally, we quantitatively assessed the capacity of hiAstrocytes to synthesize and export the antioxidant glutathione. In under 28 days, the generated cells express canonical and mature astrocytic markers, denoted by the expression of GFAP, AQP4 and ALDH1L1. In addition, the notion of a mature phenotype is reinforced by the expression of both astrocytic glutamate transporters EAAT1 and EAAT2. Thus, hiAstrocytes have a mature phenotype that encompasses traits critical in CNS modeling, including glutathione synthesis and secretion, upregulation of ICAM-1 and a cytokine secretion profile on a par with human fetal astrocytes. This protocol generates a multifaceted astrocytic model suitable for in vitro CNS disease modeling and personalized medicine.
人诱导多能干细胞向星形胶质细胞的分化一直受到阻碍,要么分化时间过长(超过两个月),要么分化时间较短,产生不成熟的星形胶质细胞,缺乏中枢神经系统(CNS)建模所需的重要成熟星形胶质细胞特征。我们通过在 28 天内构建一个受星形胶质细胞调控的培养环境,将稳定的 hiPSC 衍生的神经上皮干细胞定向分化为人 iPSC 衍生的星形胶质细胞(hiAstrocytes),得到了高比例的星形细胞。我们采用 RT-qPCR 和 ICC 来验证神经上皮干细胞的星形胶质细胞定向分化。为了评估炎症表型,我们用促炎细胞因子 IL-1β(白细胞介素 1 型β)刺激 hiAstrocytes,并定量评估星形胶质细胞相关细胞因子的分泌谱和细胞间黏附分子 1(ICAM-1)的表达。最后,我们定量评估 hiAstrocytes 合成和输出抗氧化剂谷胱甘肽的能力。在不到 28 天的时间里,生成的细胞表达典型的和成熟的星形胶质细胞标志物,由 GFAP、AQP4 和 ALDH1L1 的表达来表示。此外,星形胶质细胞谷氨酸转运体 EAAT1 和 EAAT2 的表达进一步证实了成熟表型的概念。因此,hiAstrocytes 具有成熟的表型,包括在中枢神经系统建模中至关重要的特征,包括谷胱甘肽的合成和分泌、ICAM-1 的上调以及与人类胎儿星形胶质细胞相当的细胞因子分泌谱。该方案生成了一个多功能的星形胶质细胞模型,适用于体外中枢神经系统疾病建模和个性化医疗。